All times are listed in CEST (Central European Summer Time)
Found 1 Presentation For Request "1796P"
1796P - Treatment patterns and survival for small cell lung cancer patients: A nationwide Danish register study
- Anders Green (Copenhagen, Denmark)
Abstract
Background
Although small cell lung cancer (SCLC) patients usually respond well to first line treatment, long-term survival remains poor. Most patients are diagnosed late with extensive disease (ED), and only limited development of new treatments has been seen over the last decades. Here, we describe treatment patterns for SCLC patients in a real-life setting in Denmark.
Methods
SCLC patients diagnosed in Denmark during 2006-2015 were identified in the Danish Cancer Registry, with follow-up through 2018. Patient- and tumor data were linked to data on co-morbidity, resection, chemoradiotherapy [CRT], radiotherapy only [RT], and chemotherapy only [CT] from the National Patient Registry. Survival was estimated using Kaplan-Meier methods.
Results
During the study period, 6,353 patients were diagnosed with SCLC. Mean age was 68.5 years, 50.8% were male, 37.1% had ≥1 co-morbidity. Overall, 68.2% had ED (stage IV), 25.7% had limited disease (LD; stage I-III), 6.1% had missing information. Death within 60 days from diagnosis, without completing treatment, was reported for 31.1% and 7.9% for ED and LD, respectively. Median survival for ED and LD was 6.2 and 15 months; and the 5-yr survival was 15% for LD and 2% for ED, respectively. Among patients with ED surviving >60 days, 5.4% received no treatment; 0.3% were resected; 3.2% received RT; 73.1% received CT; 17.9% received CRT, and 0.5% had registered prophylactic cranial irradiation (PCI). For LD, 5.3% received no treatment; 4.3% resection; 3.5% RT; 36.9% CT; 50.0% CRT; and 1.3% registered PCI. Median number of CT treatments registered during one year after initiated CT was 8 for both ED and LD. Median number of RTs registered during one year after initiated RT was 4 and 6 for patients with ED and LD, respectively.
Conclusions
Survival of SCLC patients is poor, and many patients die before completing treatment, which highlights a big unmet need for effective therapies. Recent data from clinical trials have shown survival benefit of immunotherapy in combination with chemotherapy in treatment naïve ED SCLC patients. These new treatment strategies may have the potential to improve long-term survival in this severely ill patient population.
Legal entity responsible for the study
AstraZeneca AB.
Funding
AstraZeneca AB.
Disclosure
G. Persson: Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: MSD; Speaker Bureau/Expert testimony: Takeda. K.K. Andersen, T. Hallerbäck: Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.